Difluprednate: Difference between revisions
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot |
Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Pharmacology|err |
||
| Line 34: | Line 34: | ||
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
||
| DrugBank = DB06781 |
| DrugBank = DB06781 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| ChemSpiderID = 391990 |
| ChemSpiderID = 391990 |
||
| UNII_Ref = {{fdacite|changed|FDA}} |
| UNII_Ref = {{fdacite|changed|FDA}} |
||
Revision as of 06:10, 31 August 2011
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609025 |
| License data |
|
| Routes of administration | topical dermatologic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.041.636 |
| Chemical and physical data | |
| Formula | C27H34F2O7 |
| Molar mass | 508.551 g·mol−1 |
  (what is this?) (verify) | |
Difluprednate is a corticosteroid, a derivative of prednisolone obtained by fluorination at the 6- and 9-positions, followed by esterification of the 17 and 21-hydroxyl groups with butyric acid and acetic acid, respectively (see figure). Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.
Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Sirion Therapeutics under the tradename Durezol.
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]
References
- ^ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
- ^ ClinicalTrials.gov